GILEAD SCIENCES, INC.

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes medicines across virology, oncology, and other therapeutic areas. The company's primary revenue drivers are antiviral treatments, particularly for HIV/AIDS and hepatitis C. Its HIV portfolio includes multiple fixed-dose combination products such as Biktarvy, Genvoya, and Truvada, which represent a substantial portion of company revenues. For hepatitis C, Gilead markets Epclusa and Harvoni. The company also commercializes Veklury, an intravenous antiviral used in the treatment of COVID-19.

Beyond antivirals, Gilead has developed a presence in oncology through cell therapy and targeted cancer treatments, including Yescarta, Tecartus, and Trodelvy. The company markets Letairis for pulmonary arterial hypertension and AmBisome for serious invasive fungal infections, diversifying its therapeutic footprint. Gilead operates internationally across the United States, Europe, and other markets, with a substantial research and development infrastructure supported by multiple collaboration agreements with biotechnology firms and pharmaceutical partners focused on advancing pipeline candidates in immunotherapy and small molecule development.